Positive results of a cost effectiveness study presented at the XXXIst International Workshop on Helicobacter & Microbiota in Inflammation and Cancer on September 14, 2018 in Kaunas (Lithuania). Data show that in patients with uninvestigated dyspepsia, the “Test and Treat” strategy incorporating Urea Breath Test as implemented in Spain is as effective and more cost effective than the Endoscopy-only strategy with regard to dyspepsia relief and gastric cancer prevention.


Press release

There are approximately 100,000 patients in the U.S. with EPI caused by CP according to the National Pancreas Foundation and more than 30,000 patients with EPI caused by cystic fibrosis according to the Cystic Fibrosis Foundation. Patients are currently treated with porcine pancreatic enzyme replacement pills.


(“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that in partnership with Mayoly Spindler, a European pharmaceutical company, the initiation of a Phase II clinical trial evaluating the safety and efficacy of MS1819-SD in patients with exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP).

The open-label, dose escalation Phase II study is being conducted in two sites in Australia

The Royal Adelaide Hospital and Linear Clinical Research in Perth as well as two sites in New Zealand, P3 Research in Wellington and CCST in Christchurch.  The study is projected to enroll approximately 12 patients with EPI caused by chronic pancreatitis over the next several months.  Dr. Quoc Nam Ngyuen, Associate Professor in the Department of Gastroenterology at the Royal Adelaide Hospital is the principal investigator for the study.

The primary objective of this Phase II study is to investigate the safety of escalating doses of MS1819-SD in patients with chronic pancreatitis. The secondary objective is to investigate the efficacy of MS1819-SD in these patients by analysis of the coefficient of fat absorption and its change from baseline. Initial study results from the MS1819-SD Phase II study are expected in the first half of 2017.

Read more

Paris, Wednesday, October 5, 2016

MAYOLY SPINDLER acquires the Swedish laboratory Kibion and becomes the leading company in the market of detecting and control of Helicobacter pylori infections.

Mayoly Spindler, the independent French benchmark laboratory in gastroenterology and dermocosmetics, is continuing its international development with the acquisition of the young Swedish laboratory Kibion. Mayoly Spindler has there by become the leading company in the market of urea breath tests used to diagnose the presence of Helicobacter pylori and control its eradication. stpg_coul

>Press release in english

18 October 2016  was the fourth award ceremony of Allure Russia Best of Beauty 2016 where 246 Awards  found brands-winners!

From September 2015 to September 2016 editorial staff and experienced experts tested 1700 cosmetic products from different brands and selected the best in its category!
Face, body and hair masks, serums and creams, bath products, beach and make-up!

For the first time at the fourth annual nominations were submitted-category “Pharma-Beauty”, where
SOS Repair body Cream  won its Award!!!!
We are the best drugstore cream according to the magazine Allure!!!

But! That’s not all!
We also received the award HALL OF FAME, which was rated only 4 products in category of “Pharma-beauty”, as the products apart from the competition!

We congratulate everybody with such an important first victory!

Additional information:
Magazine’s circulation: 180 000 copies
Audience: 300 900 people
Date/output frequency 12 times a year in the 20’s of every month.

Stéphane Thiroloix, new Polepharma President
Stéphane Thiroloix, CEO of Mayoly Spindler, an independent French and international pharmaceutical company and benchmark company in the field of gastroenterology and dermocosmetics, was elected President on Monday, 4 July 2016 by Polepharma’s Board of Directors.

He succeeds Guillaume Clément, President of LEO Pharma France, after three years of service.

Stéphane Thiroloix graduated from the École des Hautes Études Commerciales (HEC) [Paris Business School] and began his career at Roussel Uclaf (now Sanofi), where, for 11 years, he held roles in Marketing/Sales and General Management in South Africa, Mexico, Australia and France.

He continued his career at SmithKline Beecham (GlaxoSmithKline), where he was appointed Vice-President and Director of French Operations, and then Vice-President, Europe, Business Development and Marketing Alliances.

From 2002 to 2007, he was Vice-President of French Operations and then became Vice-President, Europe, and General Manager, France, at Bristol-Myers Squibb.

In 2007, he joined the executive committee at the Ipsen Group, a global biopharmaceutical company headquartered in France, as Executive VP, where he was in charge of Corporate Development (Business dDt and Legal Affairs, Pre-clinical and Clinical Development, Regulatory Affairs).

Before joining Laboratoires Mayoly Spindler, Stéphane Thiroloix had been working since 2011 as President, Europe, Canada, Japan and Australia, of the Advanced Surgical Devices (ASD) Division at Smith & Nephew.

Polepharma press contact: Caroline VILLEDIEU – 02 37 20 24 24 caroline.villedieu@polepharma.com

Mayoly Spindler press contact : Pascal FRUIT – 01 34 80 55 75 Pascal.Fruit@mayoly.com